Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the news. This is the proposed proprietary name for FF/VI 100/25 – 200/25 mcg, a combination of the inhaled corticosteroid (ICS) fluticasone furoate “FF” and the long acting bronchodilator (LABA) vilanterol “VI” (FF/VI). Both dosages are administered once-daily using the Ellipta, a new dry powder inhaler (DPI), making it the first once-daily, inhaled drug of its kind.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Recently, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of their candidate Relvar Ellipta in the EU. By the end of the year a final decision is expected to be made.

The CHMP recommended the approval of Relvar Ellipta only for the regular treatment of asthma in adults and adolescents –aged above 12 years. This treatment is only recommended in cases where a combination therapy is appropriate. For patients who suffer a asthma that is not sufficiently controlled with inhaled corticosteroids and short-acting inhaled beta 2-agonists the drug has been also recommended. Also, the CHMP backed the drug for the symptomatic treatment of adults suffering from chronic obstructive pulmonary disease (COPD) –term referring to chronic bronchitis and emphysema.

A day after the drug received its recommendation from the EU, Relvar Ellipta received approval also by the Japanese Ministry of Health, Labor and Welfare, for the treatment of bronchial asthma. Here it has only been approved for cases where the parallel use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required. The drug has not been approved to treat COPD. This is contrary to the status the drug possesses in the US, where it can be used to treat COPD –the third most common cause of dead- and not asthma. Subsequent to Japan’s decision, Theravance will make a milestone payment of $10 million to GlaxoSmithKline, as established on their collaboration agreement.

Last May, Theravance’s pipeline programs in collaboration with GlaxoSmithKline already received the approval of another drug, Brea Ellipta, a long term maintenance therapy of airflow obstruction and for patients suffering COPD, in the US and Canada. Although Relvar Ellipta has not been licensed or approved anywhere outside Japan for asthma treatment, it may be likely to be.

Disclosure: Pamela Gaviño holds no position in any stocks mentioned

Recommended Reading:

Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?

Could a Pair of Respiratory Disease Treatments Save This Big Pharma?

Will This Fishy Biotech Go Belly Up?

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!